

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:



Attorney Docket No.: 015270-004300US

Assistant Commissioner for Patents
Washington, D.C. 20231

On 7/12/99

TOWNSEND and TOWNSEND and CREW LLP

By: *Kevin M. Vetter*



RECEIVED

JUL 21 1998

TECH CENTER 1800/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RUBIN *et al.*

Application No.: 09/010,377

Filed: January 21, 1998

For: TREATMENT OF VIRAL
ENCEPHALITIS BY AGENTS
BLOCKING ALPHA-4 INTEGRIN
FUNCTION

Examiner: Gambel, Phillip

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed June 15, 1999, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 9, lines 22 and 23, replace "SEQ. ID. No. 1" with --SEQ ID NO:1--.

On page 9, lines 23 and 24, replace "sequence ID. No. 2" with
--SEQ ID NO:2--.